Express Pharma

US FDA votes against Novartis’ LBH589 compound

0 133

(ODAC) did not recommend the investigational compound LBH589, a pan-deacetylase inhibitor, for patients with previously treated multiple myeloma when used in combination with bortezomib [*] and dexamethasone

Novartis announced that the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) did not recommend the investigational compound LBH589 (panobinostat), a pan-deacetylase (pan-DAC) inhibitor, for patients with previously treated multiple myeloma when used in combination with bortezomib[*] and dexamethasone.

The committee’s vote will be considered by the FDA in its review of the LBH589 new drug application (NDA), but the FDA is not bound to follow the Committee’s guidance. The final decision regarding US approval is made by the FDA.

“We are disappointed by this voting outcome and believe the results from our clinical trials provide strong evidence to support LBH589 as a potential first-in-class treatment option for multiple myeloma, a cancer where an unmet patient nee